Lab grown model of a stomach cancer susceptible to resistance to different drugs depending on the patient
Drug resistance is one of the biggest hurdles in treating cancer. This is especially true for signet ring cell carcinoma (SRCC), a type of stomach cancer, which presents resistance to a variety of drugs from one patient to the next. One solution to this problem is to grow a patient’s tumour cells in the lab and test the effectiveness of different drugs before deciding which to use. However, these lab-grown cells aren’t as complex as real tumours and often don't retain the genetic changes of the original tumour. Researchers now present 3D organoids (pictured using scanning electron microscopy) made from human SRCC (top) and non-SRCC (bottom) tumours. The organoids all maintained the same genetics as the original tumours, as determined by whole exome sequencing. Notably, the SRCC and non-SRCC organoids responded differently to four different cancer drugs, highlighting the usefulness of this model for tailoring drug treatments for patients with SRCC.
BPoD stands for Biomedical Picture of the Day. Managed by the MRC London Institute of Medical Sciences the website aims to engage everyone, young and old, in the wonders of biomedicine. Images are kindly provided for inclusion on this website through the generosity of scientists across the globe.
BPoD is also available in Catalan at www.bpod.cat with translations by the University of Valencia.